Medicare Will Pick Up Tab Initially For Lower Part B Coinsurance Resulting From Price Inflation Rebates
Executive Summary
Centers for Medicare and Medicaid Services ensures that providers won’t be short-changed if beneficiary cost sharing is lowered because price inflation rebates are applied against drug costs.
You may also be interested in...
US Medicare Inflation Rebate: Limited Relief For Drugs In Shortage
CMS is updating its guidance for manufacturers on calculating inflation penalties enacted as part of the Inflation Reduction Act. The agency is outlining a policy to provide some rebate relief for drugs in shortage – but only limited relief for a short time.
Medicare Price Inflation Rebates Levied On 27 Part B Drugs In First Round; Pfizer Tops The List
Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.
Medicare Drug Price Inflation Rebate Invoice Distribution Will Start In 2025, CMS Says
Coinsurance for Part B drugs may reflect rebates by April, and sponsors are already liable for them, but payments will be delayed several years as CMS develops its systems. Agency seeks comment on how to account for 340B discounts and make allowances for drug shortages, among other issues.